Classification of five SARS-CoV-2 serotypes based on RBD antigenicities
Science Bulletin · 2023-12 · 68 (23) · 3003-3012
DOI: 10.1016/j.scib.2023.09.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Bulletin, 2023-12. Verfasst von Shixiong Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, I…. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a significant number of variants, particularly with the emergence of Omicron with many sub-variants. These variants have exhibited increased immune escape, leading to reduced efficacy of existing vaccines and therapeutic antibodies. Given the diminished cross-neutralization observed among these variants, it is plausible that SARS-CoV-2 has developed multiple serotypes. As the major antigenic site, the receptor-binding domain (RBD) of viral spike (S) protein was chosen for serotyping. We selected 23 representative variants, including pre-Omicron variants and Omicron sub-variants, and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs. Each serotype includes several genetically distinct variants. Serotype-I encompasses all pre-Omicron variants (with two subtypes), while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution. We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants, and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019 (COVID-19).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101,…
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; School of Life Sciences, Yunnan University, Kunming 650091, China.
- School of Life Sciences, Peking University, Beijing 100871, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
- State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
- Faculty of Health Sciences, University of Macau, Macau 999078, China.
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
- Institute of Microbiology, Chinese Academy of Sciences
Zitieren
APA
Hu, S., Wu, C., Wu, X., Ma, X., Shu, C., Chen, Q., Zheng, A., Yang, H., Lu, J., Du, P., Gao, G. F., & Wang, Q. (2023). Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Science Bulletin, 68(23), 3003-3012. https://doi.org/10.1016/j.scib.2023.09.048
Vancouver
Hu S, Wu C, Wu X, Ma X, Shu C, Chen Q, et al. Classification of five SARS-CoV-2 serotypes based on RBD antigenicities. Science Bulletin. 2023;68(23):3003-3012. doi:10.1016/j.scib.2023.09.048
BibTeX
@article{Hu2023,
author = {Hu, Shixiong and Wu, Chunli and Wu, Xinkai and Ma, Xuehui and Shu, Chang and Chen, Qian and Zheng, Anqi and Yang, Huiting and Lu, Jian and Du, Pei and Gao, George Fu and Wang, Qihui},
title = {Classification of five SARS-CoV-2 serotypes based on RBD antigenicities},
journal = {Science Bulletin},
year = {2023},
volume = {68},
number = {23},
pages = {3003--3012},
doi = {10.1016/j.scib.2023.09.048}
}
EUVIMED